Epidemiological Alert, Final Statement by PAHO/WHO on Investigation of Serious Adverse Events following Receipt of Yellow Fever Vaccine Produced by Bio-Manguinhos, Brazil (27 March 2008)
Alerta Epidemiológica, Comunicación final de la OPS/OMS sobre investigación de eventos adversos graves en Perú posteriores a la vacunación con vacuna antiamarílica elaborada por Bio-Manguinhos, Brasil (27 marzo 2008)
Date
2008Metadata
Show full item recordAbstract
This PAHO/WHO statement provides results of the investigation of serious adverse events that occurred in October 2007 in Peru following administration of the yellow fever vaccine (substrain 17DD) manufactured by Bio-Manguinhos, Brazil. It contains the conclusions of the expert group as well as their recommendations. Esta comunicación de la OPS/OMS proporciona los resultados de la investigación de eventos adversos graves que ocurrieron en Perú en octubre de 2007, posteriores a la administración de la vacuna antiamarílica (sub-cepa 17DD) elaborada por Bio-Manguinhos, Brasil. Brinda la conclusión del Grupo de Expertos así como sus recomendaciones.
Subject
Collections
Related items
Showing items related by title, author, creator and subject.
-
(PAHOUnited StatesWashington, D.C., 2021)After more than 22 months of the ongoing COVID-19 pandemic in the Region of the Americas, and COVID-19 cases and deaths have been reported from all 56 countries and territories in the Region of the Americas, health systems ...
-
(2018)[ABSTRACT]. Objective. To evaluate contraindications and precautions for the yellow fever vaccine (YFV) in risk populations. Methods. A literature review was conducted by searching PubMed for “yellow fever vaccine” and ...
-
(OPSUnited StatesWashington, D.C., 2021)In 2021, three countries in the Region of the Americas (Brazil, Peru, and Venezuela) have reported confirmed yellow fever cases. In 2020, two countries in the Region of the Americas reported confirmed cases of yellow fever: ...
